WUXI XDC (02268) saw its share price climb more than 8% during the afternoon session on Thursday, with the stock last trading up 7.31% at HK$69.70, reflecting a turnover of HK$527 million.

On the news front, the company announced that its BCM3 dual-function production line for bioconjugate antibody intermediates and drug substance, located at its Singapore facility, has successfully completed GMP (Good Manufacturing Practice) release. This key achievement signals that WUXI XDC's global capacity expansion strategy has entered a new phase, which will help international clients accelerate their commercial production efforts while enabling more efficient and flexible responses to diverse capacity demands.

As an integral component of WUXI XDC's worldwide manufacturing network, the BCM3 line will work in close coordination with the BCM1 and BCM2 production lines at the Wuxi base, driving a substantial increase in capacity for antibody intermediates and conjugated drug substances. Looking ahead, according to the construction roadmap for the Singapore site, the DP4 formulation production line is scheduled to achieve GMP release by the end of August 2026.